Barts Cancer Institute, Queen Mary University of London at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Barts Cancer Institute, Queen Mary University of London takes part in 3 sessions at ESMO 2026 in Madrid. Its program spans bladder cancer, first-line treatment of metastatic triple-negative breast cancer and basic and translational research. It presents a phase 3 trial of enfortumab vedotin before surgery combined with durvalumab, with or without tremelimumab, around surgery for muscle-invasive bladder cancer.

OrganizationESMO 2026 Attendance
bci.qmul.ac.uk
University & institute
Cancer research institute of Queen Mary University of London, in London, United Kingdom, and part of a Cancer Research UK centre.
Satellite
Sat Oct 24
13:35–13:55
Navigating an evolving treatment paradigm in 1L mTNBC
AstraZeneca - Advancing 1L Breast Cancer Care Across Subtypes: Recent Developments and Future Directions
Breast cancer
Abstract
Sat Oct 24
16:54–17:06
Chair
Sun Oct 25
08:30–10:00
Rapid oral 1: Basic science and translational research
with University of Luxembourg, Clínica Universidad de Navarra
Biomarkers & precision oncology
Abstract
Sun Oct 25
08:40–08:52
Invited Discussant 4244RO and 4245RO
Rapid oral 1: Basic science and translational research
Biomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Barts Cancer Institute, Queen Mary University of London

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction